Coverage
Danish medical device maker Coloplast on Tuesday reported 7% organic revenue growth for its 2024/25 fiscal year, meeting its targets as it navigates a period of strategic and leadership transition.
Danish medical device maker Coloplast on Tuesday reported 7% organic revenue growth for its 2024/25 fiscal year, meeting its targets, and forecast a similar performance for the year ahead as it implements a new strategy.
Coloplast interim Chief Executive Lars Rasmussen will step down from the company's board of directors, the latest leadership change at the Danish medical device maker as it implements a new strategy.
Danish medical device maker Coloplast on Tuesday unveiled a new five-year strategy that tempers its long-term growth forecast.
Danish medical device maker Coloplast on Tuesday tempered its long-term growth forecast as it unveiled a new five-year strategy, dubbed "Impact4."
Danish medical device maker Coloplast announced a significant overhaul of its executive team and corporate structure on Tuesday, moves it said are designed to support a new long-term strategy.
Filings
| Filing | Date |
|---|---|
| Share buy-back week 12/2013 | 25 Mar 2013 |
| Share buy-back week 11/2013 | 18 Mar 2013 |
| Share buy-back week 10/2013 | 11 Mar 2013 |
| Share buy-back week 9/2013 | 4 Mar 2013 |
| Report on executive's transaction | 22 Feb 2013 |
| Coloplast initiates second part of the DKK 1bn share buyback programme | 22 Feb 2013 |
| Report on executive's transaction | 20 Feb 2013 |
| Report on executive's transaction | 15 Feb 2013 |
| Report on executive's transaction | 13 Feb 2013 |
| Interim financial report Q1 2012/13 | 30 Jan 2013 |
| Report on executives' transactions | 18 Jan 2013 |
| Coloplast reduces share capital | 11 Jan 2013 |